Pliant Announces Next Steps for Beacon-IPF Trial
Pliant Therapeutics has convened an external expert panel to analyze data from its paused BEACON-IPF Phase 2b trial of...
Bio-Path Holdings’ Key Clinical Breakthroughs
Bio-Path Holdings provided updates on two clinical trials: BP1001-A for solid tumors and prexigebersen for acute myeloid leukemia (AML)....
Advancing Cancer Care: The Impact of Illinois’ New Bill of Rights
In this interview, we conversed with Pete Govorchin, President, City of Hope® Cancer Center Chicago and Edward S. Kim,...
CertisAI Predictive Oncology Intelligence Platform Awarded US Patent
Certis Oncology Solutions received patent approval for its predictive AI/ML platform, CertisAI™, designed to forecast drug response using gene...
Neuphoria Therapeutics Gets $15M Milestone Payment from Merck
Neuphoria Therapeutics (Nasdaq: NEUP) will receive a $15 million milestone payment from Merck due to the initiation of a...
Bio-Path Holdings Announces Promising Phase 1/1b AML Trial Results
Bio-Path Holdings announced positive findings from its Phase 1/1b clinical trial of BP1002, a drug designed to treat refractory/relapsed...
Updated Phase 2 Agent-797 Gastric Cancer Data at AACR IO
MiNK Therapeutics will present interim Phase 2 data on AgenT-797 combined with botensilimab and balstilimab for refractory gastric cancer...
Orchestra Biomed Announces Favorable AVIM Therapy Data for Heart Failure at THT 2025
Orchestra BioMed Holdings announced positive data from a retrospective analysis of its MODERATO II study, demonstrating that atrioventricular interval...
Windtree Therapeutics Presents Late-Breaking Istaroxime Data at Heart Failure Conference
Windtree Therapeutics announced a presentation on its drug istaroxime at the Technology and Heart Failure Therapeutics Conference. The presentation...
Escharex’s Pivotal Trial for Venous Leg Ulcers
MediWound has launched VALUE, a pivotal Phase III trial for EscharEx®, its enzymatic treatment for venous leg ulcers (VLUs)....